GLP-1 agonists and analogs play a central role in managing type 2 diabetes mellitus (T2DM) and obesity, with long-acting formulations or prolonged use of short-acting ones potentially reducing gastric emptying due to tachyphylaxis [6]. This evidence concerns the gene GCG and obesity due to melanocortin 4 receptor deficiency.